Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00568802 · ClinicalTrials.gov registry record · Phase 1
A Pilot Therapeutic Trial Using Hydroxyurea in Type II and Type III Spinal Muscular Atrophy Patients
A Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT00568802: Completed Phase 1 study, sponsored by Stanford University.
NCT00568802 is a Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 27 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00568802, a Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The objectives of this trial are: to establish a safety profile for use of Hydroxyurea in children with Types II and III Spinal Muscular Atrophy; to identify reliable outcome measures for HU treatment in Types II and III SMA; and to detect the clinical efficacy of HU treatment in children with Types II and III SMA.
Interventions
- DRUG Hydroxyurea
- DRUG Placebo to match hydroxyurea
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2004-01 |
| Est. Completion | 2010-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00568802
The ClinicalTrials.gov registry entry for NCT00568802 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Hydroxyurea is the first listed.
NCT00568802 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00568802 about?
NCT00568802 is a clinical study titled "A Pilot Therapeutic Trial Using Hydroxyurea in Type II and Type III Spinal Muscular Atrophy Patients". The objectives of this trial are: to establish a safety profile for use of Hydroxyurea in children with Types II and III Spinal Muscular Atrophy; to identify reliable outcome measures for HU treatment in Types II and III SMA; and to detect the clinical efficacy of HU treatment in children with Types...
What is the current status of trial NCT00568802?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2004-01. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00568802?
The interventions under investigation include: Hydroxyurea (DRUG), Placebo to match hydroxyurea (DRUG).
Who is sponsoring clinical trial NCT00568802?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.